摘要
目的探讨癌基因蛋白质v-akt(Akt2)特异性siRNA对人肺癌细胞株NCI—H446细胞顺铂化疗敏感性的影响及对耐药蛋白的调控作用。方法构建针对Akt2基因mRNA的siRNA,利用脂质体转染肺癌细胞NCI-H446,反转录-PCR检测Akt2-mRNA的表达,免疫细胞化学法检测肺耐药相关蛋白(LRP)及P糖蛋白(P-gP)的表达。以顺铂分别作用于对照组、未转染组、阴性质粒组及转染组细胞24h后,噻唑蓝(MTr)比色法检测细胞的增殖,流式细胞仪检测细胞的凋亡。结果转染Akt2-siRNA后,NCI-H446细胞Akt2-mRNA表达明显降低,转染组肺癌细胞LRP及P-gP表达水平显著低于未转染组(P〈0.01)。细胞的增殖率从(60.2±2.8)%下降到(34.7±2.6)%(P〈0.01),凋亡率从(19.3±1.6)%上升到(38.8±1.2)%(P〈0.01)。结论Akt2特异性siRNA可明显下调Akt2的表达,提高NCI—H446细胞对化疗的敏感性;它可能是通过下调LRP和P—gp蛋白的表达,部分逆转NCI-H446细胞对顺铂的耐药性。
Objective To explore the effects of oncogene protein v-akt-siRNA on the sensitivity of human lung cancer cell line NCI-H446 to cisplatin and drug resistance proteins in human lung cancer ceils. Methods The small interfering siRNA expression vector targeting Akt2 gene (siAkt2) was constructed. And the NCI-H446 cells were transfected with negative control vector or siRNA vector. The expressions of Akt2-mRNA and lung resistance-related protein (LRP) and P-glycoprotein (P-gp) were detected by reverse transcription-polymerase chain reaction and immunocytochemistry respectively. NCI- H446 and transfected cells were treated by cisplatin for 24 h. The cell proliferation was measured by 3- (4, 5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT) assay and cell apoptotic rate detected by flow cytometry. Results Akt2-mRNA decreased significantly in the transfected NCI-H446 cells versus the non- transfection group. And the expressions of LRP and P-gp proteins decreased significantly in the transfection group versus the control group (P 〈 0. 01 ). The cell proliferation rate decreased from (60. 2 ± 2. 8) % to (34.7 ±2.6)% (P〈0.01). The cell apoptotic rate increased from (19.3 ±1.6)% to (38.8 ±1.2)% after a therapy of cisplatin ( P 〈 0. 01 ). Conclusion The siRNA targeting Akt2 can decrease the Akt2 expression, increase the chemotherapeutic sensitivity to cisplatin and partially reverse the cisplatin resistance of NCI-H446. The mechanism may be through the lowered expressions of LRP and P-gp.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2011年第30期2139-2142,共4页
National Medical Journal of China
基金
河南省医学高新技术发展扶持项目(20060035)